Radiolabeled somatostatin analogues (SSAs) were initially developed for the purpose of imaging SSTR type 2 (SSTR-2) expressions in gastroenteropancreatic (GEP)-NETs as these generally express SSTR-2 correlated to tumor grade [28,29]. This evidence concerns the gene SSTR2 and neoplasm.